Zeke Capital Advisors LLC Sells 1,318 Shares of Becton Dickinson and Co (NYSE:BDX)

Zeke Capital Advisors LLC decreased its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 28.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,385 shares of the medical instruments supplier’s stock after selling 1,318 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Becton Dickinson and were worth $856,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Eagle Asset Management Inc. acquired a new stake in Becton Dickinson and in the 2nd quarter worth about $2,062,000. GAM Holding AG raised its stake in Becton Dickinson and by 56.4% in the 2nd quarter. GAM Holding AG now owns 48,870 shares of the medical instruments supplier’s stock worth $12,316,000 after purchasing an additional 17,622 shares in the last quarter. CIBC Asset Management Inc raised its stake in Becton Dickinson and by 0.5% in the 2nd quarter. CIBC Asset Management Inc now owns 53,480 shares of the medical instruments supplier’s stock worth $13,477,000 after purchasing an additional 247 shares in the last quarter. Black Diamond Financial LLC acquired a new stake in Becton Dickinson and in the 2nd quarter worth about $562,000. Finally, Findlay Park Partners LLP raised its stake in Becton Dickinson and by 8.3% in the 2nd quarter. Findlay Park Partners LLP now owns 2,220,000 shares of the medical instruments supplier’s stock worth $559,462,000 after purchasing an additional 170,000 shares in the last quarter. Institutional investors and hedge funds own 84.26% of the company’s stock.

Several brokerages have weighed in on BDX. Wells Fargo & Co lifted their price objective on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Raymond James lifted their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 28th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Piper Jaffray Companies dropped their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $266.55.

Shares of Becton Dickinson and stock opened at $258.59 on Monday. The firm has a market capitalization of $69.32 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 1.64 and a beta of 1.12. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The firm’s 50 day moving average is $254.23 and its 200 day moving average is $246.15. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $264.74.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm’s revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.91 EPS. As a group, research analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

In related news, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the sale, the senior vice president now directly owns 5,180 shares of the company’s stock, valued at approximately $1,347,214.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Alexandre Conroy sold 9,829 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total transaction of $2,506,984.74. Following the sale, the executive vice president now directly owns 16,535 shares in the company, valued at $4,217,417.10. The disclosure for this sale can be found here. Insiders have sold a total of 37,249 shares of company stock worth $9,616,803 over the last ninety days. 0.12% of the stock is currently owned by insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is operating income?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.